Eli Lilly Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Eli Lilly kazanç ve gelirin sırasıyla yıllık 17.5% ve 12.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 52.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

17.5%

Kazanç büyüme oranı

17.56%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.1%
Gelir büyüme oranı	12.3%
Gelecekteki özkaynak getirisi	52.32%
Analist kapsamı	Good
Son güncelleme	06 Feb 2026

Gelecekteki son büyüme güncellemeleri

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Feb 07

Recent updates

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Feb 07

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Nov 25

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 07

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Sep 19Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Eli Lilly and Company Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

May 05

Kazanç ve Gelir Büyüme Tahminleri

NYSE:LLY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	105,274	44,071	32,008	N/A	18
12/31/2027	92,214	36,247	25,233	N/A	25
12/31/2026	79,521	30,688	16,103	N/A	25
12/31/2025	65,179	20,640	N/A	N/A	N/A
9/30/2025	59,420	18,412	7,038	16,062	N/A
6/30/2025	53,258	13,800	551	10,938	N/A
3/31/2025	49,003	11,106	-668	9,318	N/A
12/31/2024	45,043	10,590	1,016	8,818	N/A
9/30/2024	40,863	8,370	-2,275	6,032	N/A
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,469	6,215	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	N/A	4,322	N/A
6/30/2019	21,673	4,103	N/A	4,933	N/A
3/31/2019	21,622	2,545	N/A	5,399	N/A
12/31/2018	21,493	3,151	N/A	5,525	N/A
9/30/2018	22,016	372	N/A	5,819	N/A
6/30/2018	22,368	-166	N/A	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LLY 'nin tahmini kazanç büyümesi (yıllık 17.5% ) tasarruf oranının ( 3.4% ) üzerindedir.

Kazançlar ve Piyasa: LLY şirketinin kazançlarının (yıllık 17.5% ) US pazarından (yıllık 15.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: LLY şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: LLY şirketinin gelirinin (yıllık 12.3% ) US pazarından (yıllık 10.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LLY şirketinin gelirinin (yıllık 12.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LLY 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 52.3 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/02/08 23:36
Gün Sonu Hisse Fiyatı	2026/02/06 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Eli Lilly and Company 50 Bu analistlerden 25, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Kerry Holford	Berenberg
Courtney Breen	Bernstein

Eli Lilly Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Recent updates

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Upcoming dividend of US$1.73 per share

Now 24% undervalued

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Chairman & CEO exercised options and sold US$15m worth of stock

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Dividend of US$1.73 announced

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Now 20% undervalued

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Price target increased by 7.4% to US$1,007

Price target increased by 7.8% to US$993

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Second quarter dividend of US$1.50 announced

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years

Investor sentiment improves as stock rises 16%

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast Cancer

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of Mounjaro

Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3

Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research Investment

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of Jaypirca

Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung Cancer

Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE Trial

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 Trial

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Chairman recently bought US$1.1m worth of stock

Ken Paxton Files Lawsuit in State Court Against Eli Lilly and Co

Chairman recently bought US$1.1m worth of stock

Chairman recently bought US$1.1m worth of stock

New major risk - Earnings quality

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of US$1.50 per share

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Eli Lilly and Company Announces Topline Results from SURPASS-CVOT

Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 Study

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of Jaypirca

Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025

Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease

First quarter dividend of US$1.50 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025